Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 7, 2005
- Sales of JCROA Member Firms Increase 22.6% in 2004
March 7, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 7, 2005
- Results of Survey on Ethical Drug Development Announced: Fuji-Keizai
March 7, 2005
- OTC Drug Industry Should Take Advantage of Booming Health Food Market: Mr Futagawa of MED
March 7, 2005
- BUSINESS NEWS IN BRIEF
March 7, 2005
- Experts Generally Agree on Risk Assessment Method for OTC Drugs
March 7, 2005
- PRESS SEMINAR
March 7, 2005
- OTC NEWS IN BRIEF
March 7, 2005
- Aiming for Sales of \100 Bil. in 2005: Mr Ohsawa of NBI
March 7, 2005
- DIAGNOSTIC NEWS IN BRIEF
March 7, 2005
- Taisho Toyama to Unify Compensation, Promotion Systems for MRs
February 28, 2005
- 1st 3 Qtrs Business Results -1-
February 28, 2005
- Nippon Chemiphar Aims to Double GE Sales by FY2007
February 28, 2005
- 1st 3 Qtrs Business Results -2-
February 28, 2005
- Sawai Announces Revised 3-year Management Plan
February 28, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 28, 2005
- MREAC to Begin Improving Education, Training System
February 28, 2005
- BULLETIN
February 28, 2005
- Fujisawa to Transfer Marketing of 11 Products to 3 Companies
February 28, 2005
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…